The evolution of a typical plateau lake from macrophyte to algae leads to the imbalance of nutrient retention.

Long-term anthropogenic nitrogen (N) and phosphorus (P) inputs have led to lake eutrophication and decreased environmental quality. However, the imbalance in nutrient cycling caused by ecosystem transformation during lake eutrophication is still unclear. The N, P, organic matter (OM) and their extractable forms in the sediment core of Dianchi Lake were investigated. Combining ecological data and geochronological techniques, a coupling relationship between the evolution of lake ecosystems and nutrient retention was established. The results show that the evolution of lake ecosystems promotes the accumulation and mobilization of N and P in sediments, leading to an imbalance in nutrient cycling in the lake system. From the "macrophyte-dominated" period to the "algae-dominated" period, the accumulation rates of potential mobile N and P (PMN, PMP) in sediments have significantly increased, and the retention efficiency of total N and P (TN, TP) has decreased. The increased TN/TP ratio (5.38 ± 1.52 ‒ 10.19 ± 2.94) and PMN/PMP ratio (4.34 ± 0.41 ‒ 8.85 ± 4.16), as well as the reduced humic-like/protein-like ratio (H/P, 11.18 ± 4.43 ‒ 5.97 ± 3.67), indicated an imbalance in nutrient retention during sedimentary diagenesis. Our results show that eutrophication has resulted in the potential mobilization of N in sediments exceeding P, providing new insights for further understanding the nutrient cycle in the lake system and strengthening lake management.

Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials.

BACKGROUND: To date, there has been little agreement on what drug is the "best" drug for treating severe COVID-19 patients. This study aimed to assess the efficacy and safety of different medications available at present for severe COVID-19. METHODS: We searched databases for randomized controlled trials (RCTs) published up to February 28, 2022, with no language restrictions, of medications recommended for patients (aged 16 years or older) with severe COVID-19 infection. We extracted data on trials and patient characteristics, and the following primary outcomes: all-cause mortality (ACM), and treatment-emergent adverse events (TEAEs). RESULTS: We identified 4021 abstracts and of these included 48 RCTs comprising 9147 participants through database searches and other sources. For decrease in ACM, we found that ivermectin/doxycycline, C-IVIG (i.e., a hyperimmune anti-COVID-19 intravenous immunoglobulin), methylprednisolone, interferon-beta/standard-of-care (SOC), interferon-beta-1b, convalescent plasma, remdesivir, lopinavir/ritonavir, immunoglobulin gamma, high dosage sarilumab (HS), auxora, and imatinib were effective when compared with placebo or SOC group. We found that colchicine and interferon-beta/SOC were only associated with the TEAEs of severe COVID-19 patients. CONCLUSION: This study suggested that ivermectin/doxycycline, C-IVIG, methylprednisolone, interferon-beta/SOC, interferon-beta-1b, convalescent plasma (CP), remdesivir, lopinavir/ritonavir, immunoglobulin gamma, HS, auxora, and imatinib were efficacious for treating severe COVID-19 patients. We found that most medications were safe in treating severe COVID-19. More large-scale RCTs are still needed to confirm the results of this study.